INS and myocardial infarction: The CREAT‐ECLA trial disproved what earlier trials on the benefits of glucose‐insulin and potassium (GIK) infusion in myocardial infarction showed (Fitchett David et al., 2017; Gilbert & Krum, 2015; Mamas Mamas et al., 2010; The CREATE‐ECLA Trial Group Investigators*, 2005).